Avidity Biosciences, Inc. 8-K

What Happened

• Avidity Biosciences, Inc. (RNA) filed an 8‑K on Feb 27, 2026 reporting the closing of its previously announced merger under the Merger Agreement among Avidity, Novartis AG and Ajax Acquisition Sub, Inc. As a result, each outstanding share of Avidity common stock was converted into the right to receive the agreed merger consideration and holders ceased to have stockholder rights other than that payment.
• The company notified Nasdaq on Feb 27, 2026 that the merger was consummated, requested continued trading halt (the halt was effective 8:00 p.m. ET on Feb 26, 2026) and asked Nasdaq to file a Form 25 to remove Avidity common stock from listing; trading is expected to be suspended on Nasdaq as of March 2, 2026. The company intends to file a Form 15 to terminate registration and suspend reporting obligations after Form 25 is effective.

Key Details

• Termination of equity programs: effective at or just before the Effective Time, Avidity terminated its stock plans and the employee stock purchase plan (ESPP).
• Termination of sales agreement: the Sales Agreement with TD Securities (USA) LLC, dated Aug 9, 2024, was terminated at the Effective Time.
• Management and board changes: as of the Effective Time all Avidity directors and executive officers resigned/ceased in their roles (including CEO Sarah Boyce and listed directors). Directors and officers of the Merger Sub (Jaime Huertas and Eduard Marti as directors; John McKenna as President, Eduard Marti as Treasurer, Jamie Huertas as Secretary) became the leadership of the surviving corporation.
• Shareholder impact: outstanding Avidity shares converted into merger consideration (no post‑closing stockholder rights except to receive that consideration), subject to applicable withholdings.

Why It Matters

• Liquidity and public reporting: delisting and anticipated termination of registration (Form 25 and Form 15) mean Avidity common stock will no longer trade on Nasdaq and the company will stop filing SEC periodic reports, reducing public access to ongoing financial disclosures and secondary market liquidity.
• For shareholders and employees: holders of common stock will receive the merger consideration instead of continuing as public shareholders; employees holding equity awards or ESPP interests should expect those plans were terminated and should review the merger documents for payout or treatment details and any tax/withholding implications.
• For investors: this is a completed acquisition event, not an earnings report—focus on the Merger Agreement terms (previously filed) for the exact cash/stock consideration and timelines, and contact your broker or the company’s investor relations for questions on payments or claim procedures.